Dasatinib drugs are used in the treatment of various cancers like Chronic Myeloid Leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). These drugs selectively inhibit the BCR-ABL tyrosine kinase, which is responsible for the creation of the abnormal BCR-ABL fusion gene product that causes CML and Ph+ ALL. Dasatinib proves to be more effective compared to the first-generation tyrosine kinase inhibitors and has fewer side effects. The global Dasatinib Drugs ... Read more
